Skip to main content
Erschienen in: Digestive Diseases and Sciences 3/2016

01.03.2016 | Original Article

Time Trends, Clinical Characteristics, and Risk Factors of Chronic Anal Fissure Among a National Cohort of Patients with Inflammatory Bowel Disease

verfasst von: Hoda M. Malaty, Shubhada Sansgiry, Avo Artinyan, Jason K. Hou

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Chronic anal fissure (CAF) is a common problem that causes significant morbidity. Little is known about the risk factors of CAF among patients with inflammatory bowel disease (IBD).

Aim

To study the clinical characteristics and prevalence of CAF among a cohort of IBD patients.

Methods

We performed a population-based study on IBD patients from the National Veterans Affairs administrative datasets from 1998 to 2011. IBD and AF were identified by ICD-9 diagnosis codes.

Results

We identified 60,376 patients with IBD between the ages of 18–90 years, 94 % males, 59 % diagnosed with ulcerative colitis (UC), and 88 % were Caucasians. The overall prevalence of CAF was 4 % for both males and females. African Americans (AA) were two times more likely to have CAF compared to Caucasians (8 vs. 4 %; OR 2.0, 95 % CI 1.6–20.2, p = 0.0001) or Hispanics (8 vs. 4.8 %; OR 2.1, 95 % CI 1.4–25.2, p = 0.0001). The prevalence of CAF significantly dropped with age from 7 % at age group 20–50 to 1.5 % at 60–90 (p = 0.0001). CD patients were two times more likely to have CAF than UC patients (6 vs. 3 %; OR 1.9, 95 % CI 1.5–18.2, p = 0.0001). The initial diagnosis of CAF occurred within 14 years after the initial diagnosis of IBD in 74.5 % patients.

Conclusions

CAF is more prevalent among IBD than what is reported in the general population and diagnosed after the diagnosis of IBD. CAF is more prevalent among patients with CD, younger patients, and AA. The current results lay the groundwork for further outcome studies relate to anal fissure such as utilization, hospitalization, and cost.
Literatur
1.
Zurück zum Zitat Madalinski MH. Identifying the best therapy for chronic anal fissure. World J Gastrointest Pharmacol Ther. 2011;14:9–16.CrossRef Madalinski MH. Identifying the best therapy for chronic anal fissure. World J Gastrointest Pharmacol Ther. 2011;14:9–16.CrossRef
2.
Zurück zum Zitat Zaghiyan KN, Fleshner P. Anal fissure. Clin Colon Rectal Surg. 2011;14:22–30.CrossRef Zaghiyan KN, Fleshner P. Anal fissure. Clin Colon Rectal Surg. 2011;14:22–30.CrossRef
3.
Zurück zum Zitat Lindsey I, Jones OM, Cunningham C, George BD, Mortensen NJ. Botulinum toxin as second-line therapy for chronic anal fissure failing 0.2 percent glyceryl trinitrate. Dis Colon Rectum. 2003;46:361–366.CrossRefPubMed Lindsey I, Jones OM, Cunningham C, George BD, Mortensen NJ. Botulinum toxin as second-line therapy for chronic anal fissure failing 0.2 percent glyceryl trinitrate. Dis Colon Rectum. 2003;46:361–366.CrossRefPubMed
5.
Zurück zum Zitat Medhi B, Rao RS, Prakash A, Prakash O, Kaman L, Pandhi P. Advances in the pharmacotherapy of chronic anal fissure: an update. Asian J Surg. 2008;3:154–163.CrossRef Medhi B, Rao RS, Prakash A, Prakash O, Kaman L, Pandhi P. Advances in the pharmacotherapy of chronic anal fissure: an update. Asian J Surg. 2008;3:154–163.CrossRef
6.
Zurück zum Zitat Mapel DM, Schum M, Worley AV. The epidemiology and treatment of anal fissures in a population-based cohort. BMC Gastroenterol. 2014;14:1–7.CrossRef Mapel DM, Schum M, Worley AV. The epidemiology and treatment of anal fissures in a population-based cohort. BMC Gastroenterol. 2014;14:1–7.CrossRef
7.
Zurück zum Zitat Lund JN, Scholefield JH. Etiology and treatment of anal fissure. Br J Surg. 1996;83:1335–1344.CrossRefPubMed Lund JN, Scholefield JH. Etiology and treatment of anal fissure. Br J Surg. 1996;83:1335–1344.CrossRefPubMed
8.
Zurück zum Zitat Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn’s disease. Dis Colon Rectum. 1981;24:22–24.CrossRefPubMed Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn’s disease. Dis Colon Rectum. 1981;24:22–24.CrossRefPubMed
9.
Zurück zum Zitat Sweeney JL, Ritchie JK, Nicholls RJ. Anal fissure in Crohn’s disease. Br J Surg. 1988;75:56–57.CrossRefPubMed Sweeney JL, Ritchie JK, Nicholls RJ. Anal fissure in Crohn’s disease. Br J Surg. 1988;75:56–57.CrossRefPubMed
10.
Zurück zum Zitat Fleshner PR, Schoetz DJ Jr, Roberts PL, Murray JJ, Coller JA, Veidenheimer MC. Anal fissure in Crohn’s disease: a plea for aggressive management. Dis Colon Rectum. 1995;38:1137–1143.CrossRefPubMed Fleshner PR, Schoetz DJ Jr, Roberts PL, Murray JJ, Coller JA, Veidenheimer MC. Anal fissure in Crohn’s disease: a plea for aggressive management. Dis Colon Rectum. 1995;38:1137–1143.CrossRefPubMed
11.
Zurück zum Zitat Hou JK, Tan M, Stidham RW, et al. Accuracy of diagnostic codes for identifying patients with ulcerative colitis and Crohn’s disease in the Veterans Affairs Health Care System. Dig Dis Sci. 2014;59:2406–2410.CrossRefPubMed Hou JK, Tan M, Stidham RW, et al. Accuracy of diagnostic codes for identifying patients with ulcerative colitis and Crohn’s disease in the Veterans Affairs Health Care System. Dig Dis Sci. 2014;59:2406–2410.CrossRefPubMed
12.
Zurück zum Zitat Isene R, Bernklev T, Høie O, et al. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2015;50:300–305.CrossRefPubMed Isene R, Bernklev T, Høie O, et al. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2015;50:300–305.CrossRefPubMed
13.
Zurück zum Zitat Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110–119.CrossRefPubMed Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110–119.CrossRefPubMed
14.
Zurück zum Zitat Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20:213–227.CrossRefPubMed Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20:213–227.CrossRefPubMed
15.
Zurück zum Zitat Siegel CA, MacDermott RP. Is chronic pain an extraintestinal manifestation of IBD? Inflamm Bowel Dis. 2009;15:769–771.CrossRefPubMed Siegel CA, MacDermott RP. Is chronic pain an extraintestinal manifestation of IBD? Inflamm Bowel Dis. 2009;15:769–771.CrossRefPubMed
16.
Zurück zum Zitat Sofia MA, Rubin DT, Hou N, Pekow J. Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital. Dig Dis Sci. 2014;59:2228–2235.PubMedCentralCrossRefPubMed Sofia MA, Rubin DT, Hou N, Pekow J. Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital. Dig Dis Sci. 2014;59:2228–2235.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Lin KK, Sewell JL. The effects of race and socioeconomic status on immunomodulator and anti-tumor necrosis factor use among ambulatory patients with inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108:1824–1830.CrossRefPubMed Lin KK, Sewell JL. The effects of race and socioeconomic status on immunomodulator and anti-tumor necrosis factor use among ambulatory patients with inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108:1824–1830.CrossRefPubMed
18.
19.
Zurück zum Zitat Nguyen GC, LaVeist TA, Harris ML, Wang MH, Datta LW, Brant SR. Racial disparities in utilization of specialist care and medications in inflammatory bowel disease. Am J Gastroenterol. 2010;105:2202–2208.PubMedCentralCrossRefPubMed Nguyen GC, LaVeist TA, Harris ML, Wang MH, Datta LW, Brant SR. Racial disparities in utilization of specialist care and medications in inflammatory bowel disease. Am J Gastroenterol. 2010;105:2202–2208.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Nguyen GC, Munsell M, Brant SR, LaVeist TA. Racial and geographic disparities in the use of parenteral nutrition among inflammatory bowel disease inpatients diagnosed with malnutrition in the United States. J Parenter Enteral Nutr. 2009;33:563–568.CrossRef Nguyen GC, Munsell M, Brant SR, LaVeist TA. Racial and geographic disparities in the use of parenteral nutrition among inflammatory bowel disease inpatients diagnosed with malnutrition in the United States. J Parenter Enteral Nutr. 2009;33:563–568.CrossRef
21.
Zurück zum Zitat Flasar MH, Johnson T, Roghmann MC, Cross RK. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2008;14:13–19.CrossRefPubMed Flasar MH, Johnson T, Roghmann MC, Cross RK. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2008;14:13–19.CrossRefPubMed
22.
Zurück zum Zitat Sainio P. Fistula-in-ano in a defined population. Incidence and epidemiological aspects. Ann Chir Gynnaecol. 1984;73:219–224. Sainio P. Fistula-in-ano in a defined population. Incidence and epidemiological aspects. Ann Chir Gynnaecol. 1984;73:219–224.
23.
Zurück zum Zitat Abramowitz L, Batallan A. Epidemiology of anal lesions (fissure and thrombosed external hemorrhoid) during pregnancy and post-partum]. Gynecol Obstet Fertil. 2003;31:546–549.CrossRefPubMed Abramowitz L, Batallan A. Epidemiology of anal lesions (fissure and thrombosed external hemorrhoid) during pregnancy and post-partum]. Gynecol Obstet Fertil. 2003;31:546–549.CrossRefPubMed
Metadaten
Titel
Time Trends, Clinical Characteristics, and Risk Factors of Chronic Anal Fissure Among a National Cohort of Patients with Inflammatory Bowel Disease
verfasst von
Hoda M. Malaty
Shubhada Sansgiry
Avo Artinyan
Jason K. Hou
Publikationsdatum
01.03.2016
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 3/2016
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3930-3

Weitere Artikel der Ausgabe 3/2016

Digestive Diseases and Sciences 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.